Kevin received his Ph.D. from the Department of Biology at MIT, where he made important contributions to understanding the mechanisms that can contribute to cellular reprogramming. Following his doctoral studies, he launched his own group in the Department of Molecular and Cellular Biology at Harvard University.

Kevin’s laboratory at Harvard was the first in the world to show that human somatic cells can be reprogrammed to the embryonic state (via hES cell fusion). Likewise, his lab was the first to produce an iPSC-derived diseased cell type to model disease in a patient-specific manner. Currently, Kevin is a Professor of Stem Cell and Regenerative Biology at Harvard University, where his research group continues to improve approaches for reprogramming as well as pursue strategies for using iPS cells in the development of new therapeutics.